The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Tocilizumab Begins Clinical Trial for COVID-19

Tocilizumab Begins Clinical Trial for COVID-19

April 7, 2020 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

On March 25, the U.S. Food and Drug Administration authorized Genentech to initiate a randomized, double-blind, placebo-controlled phase 3 clinical trial of tocilizumab in patients with SARS-CoV-2 (COVID-19). The study will evaluate the safety and efficacy tocilizumab when added to standard care in hospitalized adults with severe pneumonia caused by COVID-19 compared with placebo plus standard care. Tocilizumab is a humanized interleukin (IL) 6 receptor antagonist approved for treating adults with moderate to severe active rheumatoid arthritis (RA) for whom one or more disease-modifying anti-rheumatic drugs has proved ineffective.1

You Might Also Like
  • Roche Gets FDA Nod for Trial to Test Arthritis Drug on COVID-19 Patients
  • Sarilumab Trial Data Shows It May Only Help Critical COVID-19 Patients
  • Sarilumab Investigated to Treat COVID-19
Also By This Author
  • Insights into Methotrexate Toxicity in Elderly Patients with Rheumatic Disease

This global study of tocilizumab will begin enrolling patients in early April 2020, with a target of approximately 330 patients. The study’s primary and secondary endpoints include clinical status, mortality, mechanical ventilation and intensive care unit variables. Patients will be followed for 60 days post-randomization, and an interim analysis will be conducted to look for early efficacy evidence.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The study is being done in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), which is part of the U.S. Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response. This trial is vital because limited published evidence exists supporting the safety and/or efficacy of tocilizumab in patients suffering from COVID-19. Additionally, tocilizumab is not currently approved by the FDA or any other health authorities for use in COVID-19 patients.

This clinical trial is the first global study of tocilizumab in a hospital setting. Currently, some independent clinical trials are exploring the efficacy and safety of tocilizumab for treating patients with COVID-19-related pneumonia. On March 3, 2020, tocilizumab was included in the seventh updated diagnosis and treatment plan for COVID-19 issued by China’s National Health Commission.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

U.S. Strategic Stockpile
Additionally, Genentech will be providing 10,000 vials of tocilizumab to the U.S. Strategic National Stockpile for potential future use at the direction of the HHS.2

The company says the current U.S. supply of tocilizumab for FDA-approved indications should not be affected by this change. Genentech has also been working with distributers to manage product supply and enable both Genentech and their distribution partners to quickly fill orders and meet patients’ medication needs.

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Genentech Inc. News release: Genentech initiates phase 3 clinical trial of Actemra in hospitalized patients with severe COVID-19 pneumonia. 2020 Mar 18.
  2. Genentech Inc. News release: Genentech announces FDA approval of clinical trial for Actemra to treat hospitalized patients with severe COVID-19 pneumonia. 2020 Mar 23.

Pages: 1 2 | Single Page

Filed Under: Drug Updates Tagged With: coronavirus, COVID-19, FDA, subcutaneous tocilizumab, tocilizumab, U.S. Food and Drug Administration (FDA)

You Might Also Like:
  • Roche Gets FDA Nod for Trial to Test Arthritis Drug on COVID-19 Patients
  • Sarilumab Trial Data Shows It May Only Help Critical COVID-19 Patients
  • Sarilumab Investigated to Treat COVID-19
  • FDA Approves Subcutaneous Tocilizumab for Ages 2–17

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)